GSK announced a $10.6 billion purchase of UK biotech Nuvalent, marking its largest deal since the 2019 Tesaro acquisition. Bernstein analysts say the size exceeds GSK’s typical targets but fits a strategic push into lung‑cancer therapies. The transaction was disclosed on Dow Jones Newswires at 4:20 ET, prompting immediate market reaction. The move follows GSK’s broader effort to diversify beyond vaccines and consumer health.

Analysts note Nuvalent differs from Tesaro in product profile; its lung‑cancer drugs offer better tolerability than existing options. GSK plans cost‑saving measures to offset the profitability dilution that plagued the Tesaro deal, which failed to generate shareholder value. Bernstein expects the combined entity to capture a larger share of the $8 billion global lung‑cancer market. The firm hopes its global reach will amplify Nuvalent’s market potential.

Shares of GSK slipped 1.3% after the announcement, reflecting investor concern over the deal’s scale and integration risk. If GSK successfully leverages Nuvalent’s pipeline, the acquisition could restore growth momentum absent since the Tesaro purchase. Analysts will monitor GSK’s post‑deal cost structure and any regulatory approvals required for Nuvalent’s products. The market now watches how quickly GSK can translate the deal into earnings uplift.